Bala Gamage Nalaka Hasith Maduranga

Mr. Bala Gamage Nalaka Hasith Maduranga

Department of Marine Bioscience and Environment, College of Ocean Science and Technology, Korea Maritime and Ocean University, Busan, Republic of Korea
orcid
Korea Maritime and Ocean University, Busan 49112, Korea

Research Focus & Metrics

Academic Career Length

2Years (2025-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
31 December 2025 in Fisheries and Aquatic Sciences
Verified
Journal Article
Open access
PDF file
HJHettiarachchige Priyanga Sajeewanie Jayapala
Hettiarachchige Priyanga Sajeewanie Jayapala
Bala Gamage Nalaka Hasith MadurangaBala Gamage Nalaka Hasith Maduranga
Bala Gamage Nalaka Hasith Maduranga
DHDwi Haryanti
Dwi Haryanti
NPNimal Punyasiri
Nimal Punyasiri
VGVishmi Gunasinghe
Vishmi Gunasinghe
SLSun Young Lim
Sun Young Lim
Fisheries and Aquatic Sciences

4 October 2026 in Epigenomes
Verified
Journal Article
Open access
PDF file
Bala Gamage Nalaka Hasith MadurangaBala Gamage Nalaka Hasith Maduranga
Bala Gamage Nalaka Hasith Maduranga
HYHee Doo Yang
Hee Doo Yang
SLSu In Lee
Su In Lee
JEJung Woo Eun
Jung Woo Eun
SLSun Young Lim
Sun Young Lim
JJJee-Yeong Jeong
Jee-Yeong Jeong
Hepatocellular carcinoma (HCC) is a major cause of cancer-related mortality worldwide. Emerging evidence has established N6-methyladenosine (m6A) RNA methylation as a key epitranscriptomic mechanism underlying hepatocarcinogenesis. Methyltransferase-like 3 (METTL3), the catalytic core of the m6A methyltransferase complex (MTC), forms a heterodimer with METTL14 and cooperates with auxiliary components of the MTC to deposit m6A modifications that modulate mRNA stability, splicing, nuclear export, and translation. In this review, we comprehensively summarize the current understanding of METTL3 biology in HCC, focusing on its structure, assembly within the MTC, regulation of coding and non-coding RNAs, and its roles in driving key oncogenic signaling cascades, such as JAK/STAT3, PI3K/AKT/mTOR, Wnt/β-catenin, Hippo/YAP, Notch, Hedgehog, and epithelial–mesenchymal transition. In addition, we discussed how METTL3 remodels the tumor immune microenvironment (TIME) by regulating immune responses and metabolic pathways promoting immune evasion and therapy resistance. Therapeutic strategies targeting METTL3—including small-molecule inhibitors, CRISPR-Cas9 approaches, combination immunotherapy, and tumor-selective delivery systems—are discussed together with the challenges that continue to limit clinical translation. Collectively, these findings position METTL3 as a central epitranscriptomic regulator of HCC progression; however, further mechanistic and clinical validation remains necessary to establish its utility as a therapeutic target and prognostic biomarker.